TUNE INTO @TheDalesReport AT 4:25PM EST
Harv Johal (CRO) and Sean Karl (PM) explain how countries like Australia, Germany, Israel, and parts of Europe treat CBD APIs, GMP manufacturing and pharmacy distribution much differently than the U.S. market.
(link below)
🎦 TRADE TO BLACK -- Presented by @FlowhubCo
🎙️ @FundCanna CEO @AdamStettner
- $60M injection!
🎙️ Deepank Utkhede, @vantagehemp COO
+
🎙️ Christian Santi, Sales Director
- Which CBD companies are Pharma grade?
🌿 ETFs: 🌎 $YOLO 🇺🇸 $MSOS
▶️ LIVE @ 4pm
https://t.co/vO0nU0DvPo
"From FDA Drug Master Files and global GMP certifications to clinical trial readiness and healthcare integration, Vantage Hemp is positioning itself very differently than most of the industry."
Tune into @TheDalesReport now! (link below)
Tune in at 40 minutes and learn why healthcare operators, pharmacy leaders, and accountable care organizations are paying attention to Dr. Shields
https://t.co/vCJ0NkrPNc
Vantage Standard is now a weekly segment @TheDalesReport
Tune in at the 40 minute mark of last week's episode as Dr. Paul Shields passionately explains his REACH ACO-targeted Neuropathic Pain Medication Optimization Pathway.
Watch the interview in the next post.
TODAY @ 4PM EST - Rusty Kuchta and Dr. Paul Shields join The Dales Report to discuss:
• The Medicare Substance Access BEI Pilot
• Neuropathic Pain Optimization Pathways
• CBD as a value-based healthcare intervention
Watch live @TheDalesReport#CBD#Healthcare#Medicare
Vantage Hemp appoints Rusty Kuchta, RPh as CEO
Rusty is a pharmacist and entrepreneur with 25+ years across retail, LTC, hospice, and PBM. As the Medicare CBD pilot takes flight, pharmacy + benefits integration will define program success.
#Medicare#ACO#CBD#ValueBasedCare
Dr. Paul Shields joins Vantage Hemp as CMO to lead strategy for the emerging Medicare CBD pilot.
• REACH ACO + oncology pathway expertise
• Clinical governance + formulary design
• Pharma-grade, DMF-backed CBD APIs
Dr. Shields will drive execution inside value-based care.
Last month’s Executive Order on rescheduling marks a meaningful shift for our industry. To help our customers and partners understand the implications, we teamed up with The Distrio to produce:
"Schedule 3 and Vantage Hemp: Trump's Rescheduling and CBD for Medicare"
#Schedule3
President Donald Trump’s recent executive order rescheduling cannabis to a Schedule III controlled substance marks the most momentous shift in U.S. federal drug policy since 1970.
We used DistrioGPT to produce a deep dive report on what this means for pharmaceutical grade CBD producer, Vantage Hemp Co.
If you are curious about the potential changes to cannabis regulation in the United States, this report is a helpful resource. (Link in reply)
and we look forward to serving you all.
If you need help migrating your business to a safe and certified hemp supply chain, please contact our team.
https://t.co/lta2A77Ygt
HEMP BAN UPDATE:
Vantage Hemp is a leading global producer of pharmaceutical grade hemp-derived cannabinoids. We are experts in producing low-THC and non-detectable THC products. We do not produce THC products of any kind. We do not produce synthetic cannabinoids.
1 / 🧵
Vantage Hemp’s team of expert scientists and quality assurance professionals is capable of meeting the most stringent global specifications. We are confident that we'll continue to manufacture a wide range of hemp-derived cannabinoid based products in the United States,
3/